TetraKit Technologies is participating in PRE-CISE, a newly launched €1 million Eurostars-funded R&D collaboration led by Akiram Therapeutics, with Danish partner PreTT. The project aims to develop next-generation targeted alpha therapies using an innovative pretargeting strategy. By separating the tumor-targeting and therapeutic steps, the approach seeks to overcome current limitations in radioimmunotherapy, enhancing precision and minimizing toxicity.

Akiram Therapeutics (Sweden) leads the project with its proprietary CD44v6-targeting antibody platform, already being evaluated clinically in its lead candidate 177Lu-AKIR001. The PRE-CISE project builds on this platform to expand into alpha-emitting therapies.
PreTT (Denmark) contributes its cutting-edge pretargeting technology, which enables monoclonal antibodies to be used more effectively in radioligand therapy by improving tumor selectivity and reducing exposure to healthy tissue.
TetraKit Technologies (Denmark) provides its versatile TetraKit Platform for stable and efficient radiolabeling with alpha-emitting isotopes such as astatine-211, essential for the therapeutic payload in the pretargeting system.

This two-step approach, targeting tumors first then delivering the radiotherapeutic component, could unlock the potential of alpha-emitters for use in antibody-based therapies, significantly expanding the landscape of precision oncology.